Maher Rabah, DO
Interventional Cardiology · Berkley, MINPI 1013967793
Payments from drug & device makers
Across 77 payments — averaging $45.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Inari Medical, Inc.$870
- Abiomed$248
- Medtronic$116
- E.r. Squibb & Sons, L.L.C.$15
- Biotronik Inc.$13
What the payments were for
- Speaking & faculty fees$1,23635%
- Travel & lodging$75721%
- Food & beverage$1,54644%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 66 | $2,276 |
| Inari Medical, Inc. | 5 | $870 |
| Abiomed | 3 | $248 |
| Medtronic | 1 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Biotronik Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioJet XMI$1,236
- FLOWTRIEVER CATHETER, S$757
- CT THROMBECTOMY SYSTEM KIT$757
- SYNERGY$125
- ONYX FRONTIER$116
- Impella$107
- COMET$102
How this compares
$3,539 in reported general payments places this provider in the 30th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 575 | $643,710 |
| Repatha SureclickEvolocumab | 313 | $269,320 |
| EntrestoSacubitril/Valsartan | 233 | $262,955 |
| JardianceEmpagliflozin | 140 | $149,118 |
| XareltoRivaroxaban | 107 | $127,916 |
| Praluent PenAlirocumab | 75 | $66,784 |
| Rosuvastatin Calcium | 907 | $17,569 |
| Metoprolol Succinate | 918 | $15,427 |
| FarxigaDapagliflozin Propanediol | 11 | $14,128 |
| Ezetimibe | 618 | $11,503 |
| VascepaIcosapent Ethyl | 23 | $11,435 |
| ClopidogrelClopidogrel Bisulfate | 634 | $11,228 |
| Ranolazine ErRanolazine | 103 | $10,007 |
| Atorvastatin Calcium | 725 | $9,487 |
| BrilintaTicagrelor | 15 | $8,924 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Berkley
- Amr AbbasBerkley$557K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.